Multiple Treatment Interruptions and Protecting HIV-Specific CD4 T-Cells Enables Durable CTL Response and Viral Control
View ORCID ProfileAnshika Jain, View ORCID ProfileGaspar E. Canepa, Mei-Ling Liou, Emily L. Fledderman, Andrei I. Chapoval, Lingzhi Xiao, Ipsita Mukherjee, Jeffrey A. Galvin, Princy N. Kumar, José Bordon, Marcus A. Conant, Jefferey S. Boyle
doi: https://doi.org/10.1101/2023.10.24.23297421
Anshika Jain
1American Gene Technologies International, Inc., Rockville, Maryland, USA
Gaspar E. Canepa
1American Gene Technologies International, Inc., Rockville, Maryland, USA
Mei-Ling Liou
1American Gene Technologies International, Inc., Rockville, Maryland, USA
Emily L. Fledderman
1American Gene Technologies International, Inc., Rockville, Maryland, USA
Andrei I. Chapoval
1American Gene Technologies International, Inc., Rockville, Maryland, USA
Lingzhi Xiao
1American Gene Technologies International, Inc., Rockville, Maryland, USA
Ipsita Mukherjee
1American Gene Technologies International, Inc., Rockville, Maryland, USA
Jeffrey A. Galvin
1American Gene Technologies International, Inc., Rockville, Maryland, USA
Princy N. Kumar
2Division of Infectious Diseases and Tropical Medicine, Georgetown University School of Medicine, Washington D.C., USA
José Bordon
3Washington Health Institute, Washington D.C., USA
Marcus A. Conant
1American Gene Technologies International, Inc., Rockville, Maryland, USA
Jefferey S. Boyle
1American Gene Technologies International, Inc., Rockville, Maryland, USA
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Posted October 25, 2023.
Multiple Treatment Interruptions and Protecting HIV-Specific CD4 T-Cells Enables Durable CTL Response and Viral Control
Anshika Jain, Gaspar E. Canepa, Mei-Ling Liou, Emily L. Fledderman, Andrei I. Chapoval, Lingzhi Xiao, Ipsita Mukherjee, Jeffrey A. Galvin, Princy N. Kumar, José Bordon, Marcus A. Conant, Jefferey S. Boyle
medRxiv 2023.10.24.23297421; doi: https://doi.org/10.1101/2023.10.24.23297421
Multiple Treatment Interruptions and Protecting HIV-Specific CD4 T-Cells Enables Durable CTL Response and Viral Control
Anshika Jain, Gaspar E. Canepa, Mei-Ling Liou, Emily L. Fledderman, Andrei I. Chapoval, Lingzhi Xiao, Ipsita Mukherjee, Jeffrey A. Galvin, Princy N. Kumar, José Bordon, Marcus A. Conant, Jefferey S. Boyle
medRxiv 2023.10.24.23297421; doi: https://doi.org/10.1101/2023.10.24.23297421
Subject Area
Subject Areas
- Addiction Medicine (394)
- Allergy and Immunology (706)
- Anesthesia (197)
- Cardiovascular Medicine (2890)
- Dermatology (248)
- Emergency Medicine (433)
- Epidemiology (12634)
- Forensic Medicine (10)
- Gastroenterology (814)
- Genetic and Genomic Medicine (4497)
- Geriatric Medicine (411)
- Health Economics (718)
- Health Informatics (2877)
- Health Policy (1060)
- Hematology (381)
- HIV/AIDS (913)
- Medical Education (419)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4264)
- Nursing (228)
- Nutrition (626)
- Oncology (2233)
- Ophthalmology (637)
- Orthopedics (256)
- Otolaryngology (323)
- Pain Medicine (272)
- Palliative Medicine (83)
- Pathology (491)
- Pediatrics (1183)
- Primary Care Research (489)
- Public and Global Health (6846)
- Radiology and Imaging (1505)
- Respiratory Medicine (910)
- Rheumatology (431)
- Sports Medicine (378)
- Surgery (476)
- Toxicology (60)
- Transplantation (206)
- Urology (176)